Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Immunome (NASDAQ: IMNM) announced that its Compensation Committee granted inducement awards to four new employees on January 2, 2025. The awards consist of non-statutory stock options to purchase a total of 45,000 shares of common stock under the Company's 2024 Inducement Plan.

The stock options have an exercise price of $10.53 per share, matching the Company's closing price on January 2, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over the following 36 months, contingent on continued employment. These grants were approved as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• Stock-based compensation aligns employee interests with shareholders without immediate cash expenditure

Negative

• Potential future dilution of 45,000 shares for existing shareholders

BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on January 2, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 45,000 shares of common stock to four new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price per share equal to $10.53 per share, the Company’s closing sales price on January 2, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2024 Inducement Plan and the terms and conditions of an applicable stock option agreement covering the grant.

About Immunome

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugates (ADCs). In addition to a portfolio of discovery-stage ADCs, our pipeline includes AL102, a gamma secretase inhibitor currently in a Phase 3 trial for treatment of desmoid tumors, as well as IM-1021, a ROR1 ADC, and IM-3050, a FAP-targeted radioligand, both of which are the subject of INDs expected to be submitted by the first quarter of 2025. For more information, visit www.immunome.com.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include Immunome’s expectations regarding progress of its pipeline and timeline for regulatory filings; and other statements regarding forecasts for the future. These forward-looking statements are based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the risks and uncertainties described in Immunome’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 13, 2024, and in Immunome’s other filings with the SEC. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250102420836/en/

Investor Contact

Max Rosett

Chief Financial Officer

investors@immunome.com

Source: Immunome, Inc.

FAQ

How many shares were granted in Immunome's (IMNM) January 2025 inducement awards?

Immunome granted non-statutory stock options to purchase 45,000 shares of common stock to four new employees.

What is the exercise price for IMNM's January 2025 inducement stock options?

The exercise price for the stock options is $10.53 per share, which was Immunome's closing price on January 2, 2025.

What is the vesting schedule for IMNM's January 2025 inducement grants?

The options vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months.

How many new employees received IMNM stock options in the January 2025 inducement grants?

Four new employees received stock options as part of the inducement grants.